THE EFFECT OF 3 MONTHS OF RECOMBINANT HUMAN GROWTH-HORMONE (GH) THERAPY ON INSULIN AND GLUCOSE-MEDIATED GLUCOSE DISPOSAL AND INSULIN-SECRETION IN GH-DEFICIENT ADULTS - A MINIMAL MODEL ANALYSIS
Dn. Oneal et al., THE EFFECT OF 3 MONTHS OF RECOMBINANT HUMAN GROWTH-HORMONE (GH) THERAPY ON INSULIN AND GLUCOSE-MEDIATED GLUCOSE DISPOSAL AND INSULIN-SECRETION IN GH-DEFICIENT ADULTS - A MINIMAL MODEL ANALYSIS, The Journal of clinical endocrinology and metabolism, 79(4), 1994, pp. 975-983
The effect of 3 months of low dose (120 mu g/kg.week or 0.24 IU/kg. we
ek) recombinant human GH (rhGH) treatment on glucose tolerance, insuli
n secretion, and insulin- and glucose-mediated glucose disposal was ex
amined in 10 GH-deficient adults. The frequently sampled iv glucose to
lerance test was performed at baseline and after 1 week and 3 months o
f rhGH therapy and analyzed by the minimal model method of Bergman to
provide estimates of the glucose decay rate, first and second phase in
sulin secretion (Phi 1 and Phi 2), fractional clearance of insulin, an
d glucose-mediated and insulin-mediated glucose disposal. Fasting gluc
ose, insulin, C-peptide, nonesterified fatty acids (NEFA), and serum c
holesterol and triglycerides were also measured. When the 1 week data
were compared to baseline, there was a small. but significant rise in
mean (+/-SE) fasting glucose (4.62 +/- 0.17 vs. 5.1 +/- 0.15 mmol/L; P
< 0.01), NEFA (0.70 +/- 0.09 vs, 1.1 +/- 0.12 mmol/L; P < 0.005), ins
ulin (93.6 +/- 8.9 vs. 238.9 +/- 9.2 pmol/L; P(0.0001), C-peptide (0.3
2 +/- 0.13 vs. 0.66 +/- 0.13 nmol/L; P < 0.005), and Phi 1 (11.9 +/- 1
.8 vs. 16.2 +/- 1.8 pmol/L.min/mmol.L x 10(2)) and Phi 2 (1.43 +/- 0.1
7 vs. 3.15 +/- 0.25 pmol/L.min/mmol.L x 10(3); P < 0.05). Conversely,
there were associated decreases in glucose decay rate (1.83 +/- 0.26 u
s. 1.28 +/- 0.12 min(-1); P < 0.05) and insulin-mediated glucose dispo
sal (0.36 +/- 0.08 vs. 0.18 +/- 0.06 min/pmol L x 10(-4); P < 0.005).
There was no change in glucose-mediated glucose disposal or the fracti
onal clearance of insulin. By 3 months, fasting insulin and C-peptide
levels remained significantly elevated, whereas other parameters had r
eturned to baseline. There was a minor reduction in serum cholesterol
at 1 week (5.1 +/- 0.15 vs. 4.62 +/- 0.17 mmol/L; P < 0.01), which was
not maintained at 3 months. Serum triglycerides remained unchanged th
roughout the study. We conclude that short term low dose rhGH treatmen
t of GH-deficient adults induces a temporary state of mild glucose int
olerance, hyperinsulinemia, insulin resistance, and raised NEFA levels
at 1 week. By 3 months, these metabolic disturbances had returned to
baseline for a persisting modest hyperinsulinemia. Whether this hyperi
nsulinemia will last over the longer term and/or has distant detriment
al metabolic consequences in the individual must await further studies
.